Important considerations prior to elimination of breast cancer surgery after neoadjuvant systemic therapy: Listening to what our patients want
Author:
Funder
Roche
Genentech
AstraZeneca
Novartis
Sanofi
Servier
Tesaro
Pfizer
Eli Lilly
Merck
Radius Health
Servier Pharmaceuticals
Synthon Pharmaceuticals
Publisher
Elsevier BV
Subject
Oncology,Hematology
Reference6 articles.
1. Eliminating the breast cancer surgery paradigm after neoadjuvant systemic therapy: current evidence and future challenges;Heil;Ann Oncol,2020
2. Outcomes and endpoints in cancer trials: bridging the divide;Wilson;Lancet Oncol,2015
3. The attitudes of 1066 patients with cancer towards participation in randomised clinical trials;Jenkins;Br J Cancer,2010
4. Reasons for accepting or declining to participate in randomized clinical trials for cancer therapy;Jenkins;Br J Cancer,2000
5. Missed opportunities and challenges for surgical breast cancer research in the era of personalized cancer treatment;Rubio;Eur J Surg Oncol,2019
Cited by 6 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. A multidisciplinary team and patient perspective on omission of surgery after neoadjuvant systemic therapy for early breast cancer: A European Society of Surgical Oncology (ESSO) Research Academy survey;European Journal of Surgical Oncology;2024-10
2. Preferences Regarding Breast Surgery Omission Among Patients With Breast Cancer Who Receive Neoadjuvant Chemotherapy;In Vivo;2023
3. Vacuum-Assisted Breast Biopsy After Neoadjuvant Systemic Treatment for Reliable Exclusion of Residual Cancer in Breast Cancer Patients;Annals of Surgical Oncology;2021-09-28
4. A qualitative study to evaluate physician attitudes regarding omission of surgery among exceptional responders to neoadjuvant systemic therapy for breast cancer (NRG-CC006);Breast Cancer Research and Treatment;2021-03-19
5. Identification of breast cancer patients with pathologic complete response in the breast after neoadjuvant systemic treatment by an intelligent vacuum-assisted biopsy;European Journal of Cancer;2021-01
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3